文献速递炎症性肠病

开发用于克罗恩病和溃疡性结肠炎的症状与影响问卷

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2020-04-21

本研究遵循美国FDA和ISPOR指南,在美加成年患者中通过概念引出和认知访谈开发患者报告结局工具。最终形成31条目的克罗恩病症状与影响问卷(SIQ-CD)和29条目的溃疡性结肠炎症状与影响问卷(SIQ-UC),均含4个症状域和6个影响域,心理测量学验证正在进行。

要点

  • SIQ-CD含31条目,SIQ-UC含29条目,均覆盖4个症状域和6个影响域。
  • 开发过程遵循FDA和ISPOR指南,基于患者访谈和认知 debriefing。
  • 工具旨在支持CD和UC的药物标签声明,信效度验证尚在进行中。

核心结论

  • 成功开发了SIQ-CD和SIQ-UC两种患者报告结局工具,用于支持克罗恩病和溃疡性结肠炎的药物标签声明。

研究设计与样本

  • 在美加成年患者(≥18岁)中进行概念引出和认知访谈,CD概念引出纳入54例(平均年龄46.2岁,女性66.7%),UC概念引出纳入53例(平均年龄41.4岁,女性49.1%)。

主要发现

  • CD概念引出识别80个症状概念和61个影响概念,经三轮认知访谈形成31条目的SIQ-CD;UC识别79个症状概念和49个影响概念,经两轮认知访谈形成29条目的SIQ-UC。
  • 两个工具均包含4个症状域和6个影响域。

临床怎么用

  • SIQ-CD和SIQ-UC可用于临床研究中评估克罗恩病和溃疡性结肠炎患者的症状和影响,以支持监管提交。

局限性

  • 心理测量学验证研究(信度和反应度)仍在进行中,工具的测量性能尚未完全确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient-reported outcome (PRO) measures historically used in inflammatory bowel disease have been considered inadequate to support future drug labelling claims by regulatory agencies. AIMS: To develop PRO tools for use in Crohn's disease (CD) and ulcerative colitis (UC) following guidance issued by the US FDA and the ISPOR (International Society for Pharmacoeconomics and Outcomes Research). METHODS: Concept elicitation and cognitive interviews were conducted in adult patients (≥18 years) across the United States and Canada. Semi-structured interview guides were used to collect data, and interview transcripts were coded and analysed. Concept elicitation results were considered alongside existing literature and clinical expert opinion to identify candidate PRO items. Cognitive interviews evaluated concept relevance, interpretability and structure, and facilitated instrument refinement. Concept elicitation participants, except those with an ostomy, underwent centrally read endoscopy to assess inflammatory status. RESULTS: In all, 54 participants (mean age: 46.2 years; 66.7% female) were included in the CD concept elicitation interviews. In total, 80 symptom concepts and 61 impact concepts were identified. After three waves of cognitive interviews, the 31-item Symptoms and Impacts Questionnaire for CD (SIQ-CD) was developed. In the UC concept elicitation phase, 53 participants were interviewed (mean age: 41.4 years; 49.1% female). In total, 79 symptoms concepts and 49 impact concepts were identified. Following two waves of cognitive interviews, the 29-item Symptoms and Impacts Questionnaire for UC (SIQ-UC) was developed. Both instruments include four symptom and six impact domains. CONCLUSIONS: We developed PROs to support CD and UC drug labelling claims. Psychometric validation studies to evaluate instrument reliability and responsiveness are ongoing.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Jairath V, Khanna R, et al. Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2020. PMID: 32319120. doi:10.1111/apt.15726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。